• Home
  • News
  • Personal Finance
    • Savings
    • Banking
    • Mortgage
    • Retirement
    • Taxes
    • Wealth
  • Make Money
  • Budgeting
  • Burrow
  • Investing
  • Credit Cards
  • Loans

Subscribe to Updates

Get the latest finance news and updates directly to your inbox.

Top News

7 Common Cruise Scenarios Travel Insurance Won’t Cover

March 13, 2026

7 Potential Income Sources Seniors Always Forget About

March 13, 2026

Senate Passes Big Housing Reform Bill With Broad Bipartisan Support

March 12, 2026
Facebook Twitter Instagram
Trending
  • 7 Common Cruise Scenarios Travel Insurance Won’t Cover
  • 7 Potential Income Sources Seniors Always Forget About
  • Senate Passes Big Housing Reform Bill With Broad Bipartisan Support
  • 15 Cities With the Most Women in Construction
  • 38 Buc-ee’s Get ‘F’ Rating From Better Business Bureau. Here’s Why
  • 15 Smart Moves to Make When Your Job Search Hits a Wall
  • Much Ado About Taxes
  • Why Ozempic and Wegovy Might Be the Ultimate Habit-Breakers
Saturday, March 14
Facebook Twitter Instagram
FintechoPro
Subscribe For Alerts
  • Home
  • News
  • Personal Finance
    • Savings
    • Banking
    • Mortgage
    • Retirement
    • Taxes
    • Wealth
  • Make Money
  • Budgeting
  • Burrow
  • Investing
  • Credit Cards
  • Loans
FintechoPro
Home » ADRs End Mostly Higher, Missfresh and Mesoblast Trade Actively
Investing

ADRs End Mostly Higher, Missfresh and Mesoblast Trade Actively

News RoomBy News RoomAugust 7, 20231 Views0
Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Email Tumblr Telegram

By Denny Jacob

International stocks trading in New York closed mostly higher on Friday.

The S&P/BNY Mellon index of American depositary receipts edged up 0.2% to 156.41. The European index ticked up 0.1% to 149.96. The Asian index climbed 0.3% to 183.83. The Latin American index slipped 0.7% to 202.40, while the emerging-markets index was flat at 303.65.

Missfresh was among those whose ADRs traded actively.

The Chinese online grocery company soared 285% after it reported share-purchase agreements with two investors, an acquisition and the filing of its delayed 2022 annual report.

Mesoblast tumbled 59% after the Food and Drug Administration once again turned away the company’s remestemcel-L drug candidate for children with a potentially life-threatening bone marrow transplant complication, calling on the company to provide more data.

Write to Denny Jacob at [email protected]

Read the full article here

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Articles

Even Time-Strapped Business Owners Can Share an Engaging Reading Experience with Their Kids

Investing September 20, 2025

Turnover Is Costing You More Than You Think — Here’s the Fix

Investing September 19, 2025

How Pana Food Truck Started Selling Arepas

Investing September 18, 2025

Amazon CEO Andy Jassy Is Fighting Against Bureaucracy

Investing September 17, 2025

Here Are the Top 50 Mistakes I’ve Seen Kill New Companies

Investing September 16, 2025

Google Parent Alphabet Reaches $3T Market Cap

Investing September 15, 2025
Add A Comment

Leave A Reply Cancel Reply

Demo
Top News

7 Potential Income Sources Seniors Always Forget About

March 13, 20262 Views

Senate Passes Big Housing Reform Bill With Broad Bipartisan Support

March 12, 20260 Views

15 Cities With the Most Women in Construction

March 12, 20261 Views

38 Buc-ee’s Get ‘F’ Rating From Better Business Bureau. Here’s Why

March 11, 20262 Views
Don't Miss

15 Smart Moves to Make When Your Job Search Hits a Wall

By News RoomMarch 11, 2026

Editor’s Note: This story originally appeared on FlexJobs.com.Sometimes, when you’re in the midst of a…

Much Ado About Taxes

March 11, 2026

Why Ozempic and Wegovy Might Be the Ultimate Habit-Breakers

March 10, 2026

8 Genius Moves to Make When the Price of Everything Is Going Up

March 10, 2026
Facebook Twitter Instagram Pinterest Dribbble
  • Privacy Policy
  • Terms of use
  • Press Release
  • Advertise
  • Contact
© 2026 FintechoPro. All Rights Reserved.

Type above and press Enter to search. Press Esc to cancel.